Drug Combination Details
| General Information of the Combination (ID: C33680) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Thyroid cancer
[ICD-11: 2D10]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | FTC-133 | CVCL_1219 | Thyroid gland follicular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of curcumin and sorafenib showed synergetic antitumor effect in thyroid cancer cells via PI3K/Akt and ERK pathways. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | APOA1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | FASN | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JAK-1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JAK-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | LDHA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | 1*105 of H22 tumor cells were inoculated in axillae of Kunming mice (22-25 g). | |||||
| Experimental
Result(s) |
Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment. | |||||
